Iodine-131 MIBG uptake in metastatic medullary carcinoma of the thyroid. A patient treated with somatostatin.

Abstract

A 47-year-old man with multiple endocrine neoplasia (MEN) type 2a syndrome in whom metaiodobenzylguanidine (MIBG) concentrated in lesions from metastatic medullary carcinoma of the thyroid is reported. A somatostatin analogue (Sandostatin SMS 201-995) alleviated the symptoms of flushing and diarrhea associated with the elevated calcitonin levels but it did not alter either the course of the disease or the MIBG images. A review of the literature is presented of the noncatecholamine secreting tumors associated with MIBG uptake. Similarities between this case and metastatic carcinoid syndrome are discussed.

• Authors: C A Keeling, L V Basso
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 13 Issue 4 Pg. 260-3 (Apr 1988) ISSN: 0363-9762 [Print] United States
• PMID: 2897264 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Iodine Radioisotopes
• Iodobenzenes
• 3-Iodobenzylguanidine
• Somatostatin
• Octreotide

Topics

• 3-Iodobenzylguanidine
• Antineoplastic Agents (therapeutic use)
• Carcinoma (diagnostic imaging, metabolism, secondary)
• Humans
• Iodine Radioisotopes
• Iodobenzenes (pharmacokinetics)
• Male
• Middle Aged
• Multiple Endocrine Neoplasia (diagnostic imaging, drug therapy, metabolism)
• Octreotide
• Radionuclide Imaging
• Somatostatin (analogs & derivatives, therapeutic use)
• Spinal Neoplasms (diagnostic imaging, metabolism, secondary)
• Thyroid Neoplasms (diagnostic imaging, metabolism)